Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

123.28 -1.92 (-1.54%)
Streaming Delayed Price Updated: 9:44 AM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
48 49 Next >
News headline image
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
News headline image
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits ↗
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help... 
Via Benzinga
News headline image
Expert Ratings for Gilead Sciences ↗
 
Via Benzinga
News headline image
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript ↗
GILD earnings call for the period ending March 31, 2023. 
Via The Motley Fool
News headline image
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
News headline image
Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger ↗
The company sells Trodelvy and two cell therapies. Sales of all three surged. 
Via Investor's Business Daily
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
News headline image
What Does Gilead Sciences' Debt Look Like? ↗
 
Via Benzinga
News headline image
Better Buy: Pfizer vs. Gilead ↗
Pfizer and Gilead look cheap right now. 
Via The Motley Fool
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today ↗
 
Via Benzinga
News headline image
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul ↗
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
News headline image
This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
News headline image
2 Excellent Dividend Stocks to Buy for Less Than $100 ↗
Both companies are steals at current levels. 
Via The Motley Fool
News headline image
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. 
Via Benzinga
News headline image
Expert Ratings for Gilead Sciences ↗
 
Via Benzinga
News headline image
Could Gilead Sciences Stock Help You Become a Millionaire? ↗
The company's dominant HIV therapies and growing oncology pipeline are delivering. 
Via The Motley Fool
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
News headline image
A Look Into Gilead Sciences' Debt ↗
 
Via Benzinga
News headline image
Strong Quant Screens Say These 7 Growth Stocks Are a Buy ↗
StockRover’s quant screen is a grading system that brings up rewarding growth stocks to buy for income investors. 
Via InvestorPlace
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
News headline image
3 Dividend Stocks to Buy and Hold for the Next Decade ↗
Long-term investors looking for income should especially like these stocks. 
Via The Motley Fool
News headline image
Dividend Income Update March 2023 ↗
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
News headline image
If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today ↗
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
News headline image
6 Reasons to Buy Gilead Sciences Stock ↗
The healthcare stock could be a solid pillar to build your portfolio around. 
Via The Motley Fool
News headline image
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
News headline image
3 Dividend Stocks Billionaires Seem to Love ↗
It sometimes pays to follow the lead of successful people. 
Via The Motley Fool
News headline image
Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough ↗
 
Via Benzinga
News headline image
GILD - Chart Of The Week ↗
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December. 
Via Talk Markets
News headline image
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
News headline image
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis ↗
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.